Sana Biotechnology, Inc.
SANA
$3.58
-$0.02-0.56%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -26.86% | -18.61% | -12.63% | 0.61% | 14.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -30.33% | -39.23% | -16.96% | -5.36% | -14.76% |
| Operating Income | 30.33% | 39.23% | 16.96% | 5.36% | 14.76% |
| Income Before Tax | -2.97% | 32.38% | 5.82% | -10.97% | 32.29% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.97% | 32.38% | 5.82% | -10.97% | 32.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.97% | 32.38% | 5.82% | -10.97% | 32.29% |
| EBIT | 30.33% | 39.23% | 16.96% | 5.36% | 14.76% |
| EBITDA | 31.38% | 40.75% | 17.26% | 5.16% | 15.34% |
| EPS Basic | 7.58% | 42.12% | 19.95% | 2.01% | 39.24% |
| Normalized Basic EPS | 39.67% | 48.57% | 29.88% | 15.93% | 23.23% |
| EPS Diluted | 7.57% | 42.11% | 19.94% | 2.02% | 39.24% |
| Normalized Diluted EPS | 39.45% | 48.42% | 29.67% | 15.67% | 23.51% |
| Average Basic Shares Outstanding | 12.02% | 17.36% | 18.68% | 14.69% | 10.81% |
| Average Diluted Shares Outstanding | 11.56% | 16.85% | 18.15% | 14.17% | 11.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |